BioCurex公司推出检测前列腺癌新技术

一种检测前列腺癌的新型血液检测方法显示：其敏感性和特异性都要明显高于当前使用的PSA（前列腺特异抗原）方法。

BioCurex公司推出了这项检测技术。该公司认为：这种称为Recafe的检测方法使用单克隆抗体，比传统的抗血清检测方法更优越。单克隆抗体特异性更强，各批次试验具有一致性，而且易于生产。PSA检测并不是一个筛查无症状前列腺癌男性患者的合适指标，但是由于缺乏更好的检测方法，它仍然被用于常规检查。

联合使用PSA与Recafe检测能够消除单独使用PSA方法所产生的假阳性。PSA具有将问题定位于前列腺的优势，而Recaf能够确定PSA水平增高是否由于癌引起的。这种联合检测还能够将Recaf方法引入市场，因为PSA检测太普遍了。

BioCurex公司执行总裁Moro博士指出：“这种改良的检测使用单克隆抗体技术，该技术使得Milstein和Kohler获得了1984年度的诺贝尔奖”。该公司计划将其Recafe技术授权给多家健康保健公司。

Blood Test for Prostate Cancer
 
A new blood test for prostate cancer has exhibited greater sensitivity and much higher specificity than current prostate-specific antigen (PSA) tests.

The test, called Recafe, uses monoclonal antibodies and offers many advantages over the conventional antiserum test. Monoclonals are more specific, are very consistent from one batch to another, and are easy to produce, stated BioCurex, Inc. (Richmond, Canada), which developed the technology. The PSA test is not a suitable marker to screen asymptomatic men for prostate cancer, but for lack of a better test, it is used in regular checkups.

Combining the PSA and Recafe tests could eliminate the false-positives resulting from using the PSA test alone. PSA has the advantage of localizing the problem to the prostate and Recaf could then determine if the high PSA value is due to a cancer. This combination would also facilitate the introduction of Recaf into the marketplace since PSA testing is very common.

“This improved test uses monoclonal antibody technology for which Milstein and Kohler received the Nobel prize in 1984,” noted Dr. Moro, CEO of BioCurex. The company plans to license its Recafe technology to healthcare firms.